• SRAX’s subsidiary BIGtoken to enter merger with Britepool, company providing identity resolution and verification services for advertisers and publishers
• SRAX expects transaction to benefit company’s shareholders with exchange of its shares for preferred shares with blockers at 4.99% and or 9.99%
• Combined entity boasts highly experienced management team, appears poised to provide next-gen privacy-focused solutions

SRAX (NASDAQ: SRAX), a financial technology company focused on improving communications between public companies and their investors, has recently announced the merger between its subsidiary Force Protection Video Equipment Corp. (“FPVD”), also known as BIGtoken, and Britepool, an identity resolution and verification service for advertisers and publishers (https://ibn.fm/g0QqH). As part of the transaction, SRAX is expected to exchange its approximately 150 billion shares for preferred shares with blockers at 4.99% and or 9.99%. This move will allow the company to recognize the value of the asset on its balance sheet without the need to consolidate BIGtoken’s operating results. It will also allow company’s investors to recognize the true operating performance of the Sequire, its software-as-a-service platform that unlocks data and insights for publicly traded companies. SRAX expects the transaction, which is awaiting regulatory approval, to benefit the company’s shareholders. “The movement of our position to a preferred share, which is currently worth a significant amount of money, will be very beneficial for our shareholders. The market will now be able to understand the true value that SRAX is generating on its own. We are currently exploring the best way to maximize the value of this asset for our shareholders,” said Christopher Miglino, Founder and CEO of SRAX. The merger is anticipated to close in approximately thirty days. The company is positive that the combined entity boasts strong leadership. “We are excited for the BIGtoken and BritePool teams to come together for this merger. The new combined management team is incredible,” added Miglino. The new company’s CEO will be David Moore, a digital advertising pioneer who was previously a partner in BritePool. George Stella, a veteran ad tech executive and a co-founder and president of BIGtoken, will continue to serve as the president after the merger (https://ibn.fm/DwCLE). As a company offering identity resolution and verification services for advertisers and publishers, BritePool provides precise, frequency-controlled identity targeting without third-party cookies. BIGtoken serves as a data marketplace that encourages users to share information in exchange for incentives. The combined entity will aim to provide the next evolution of privacy-focused solutions, with benefits for consumers and advertisers. For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Zacks Small-Cap Research analysts recently announced coverage of Lexaria based on its market potential, valuing the company at $15 per share
• Lexaria’s patented DehydraTECH(TM) technology is undergoing clinical and pre-clinical trials for potential use in treating hypertension, viral infections and other conditions that are currently being addressed through cannabidiol-based nutraceuticals or prescription drugs
• Lexaria is also investigating alternatives to smoked or inhaled nicotine delivery to avoid lung harm, expanding the potential of its technology
• DehydraTECH’s lymph system delivery method alternative to the digestive system provides more rapid bioavailability and fewer side effects, as well as the potential for better delivery across the blood-brain barrier
• The relatively low-cost technology has the capacity to produce up to 400,000 consumer packaged goods though existing manufacturer relationships

Oral drug technology innovator Lexaria Bioscience (NASDAQ: LEXX) has drawn the attention of Zacks Small-Cap Research analysts, who have initiated coverage of Lexaria with a valuation of $15 per share because of the company’s patent portfolio supporting Lexaria’s patented DehydraTECH(TM) consumption technology and the multiple potential uses of the technology. DehydraTECH pairs active pharmaceutical ingredients (“APIs”) with select long-chain fatty acid (“LCFAs”) oils that serve as carriers for the APIs though the lymphatic system, converting these compounds into ingestible formats that can be readily administered in capsules or liquid mixtures. Zacks focuses its coverage on small and micro-cap companies it regards as under-followed or under-valued by the broader market in an effort to benefit investors as well as worthy innovators (https://ibn.fm/9XRDS). “Interest in using (DehydraTECH) extends across many categories beyond the primary pharmaceutical focus of the company from foods to beauty products and nutraceuticals, and across a range of formats from oral ingestible to oral buccal/sublingual to topical products,” Zacks notes in a news release issued Sept. 23 (https://ibn.fm/3FTTE). But thus far, Lexaria’s testing has focused on potential uses of DehydraTECH in treating high blood pressure (hypertension) in combination with cannabidiol (“CBD”), as well as in battling viruses through combination with such antivirals as remdesivir and colchicine and in providing alternatives to tobacco smoking through nicotine replacement therapy oral pouches. Clinical and preclinical studies have advanced Lexaria’s API toward commercialization in these areas, but DehydraTECH is already being used in CBD-based nutraceutical products distributed through retailers such as Albertson’s, Safeway and Hudson News stores. Zacks notes the potential market reach of Lexaria’s technology if regulatory-approved for use in pharmaceuticals, given that hypertension affects about 150 million people nationwide and over a billion worldwide, many of whom find existing medicines less than optimal. The ongoing COVID pandemic has also heightened attention on the need for antivirals to treat ever-present virus infections. And there about a billion smokers worldwide who could potentially benefit from alternative methods of delivering nicotine to avoid the lung-deleterious effects of inhaling burned or vaporized substances. Lexaria’s use of the lymphatic system for bioavailability allows APIs to achieve more rapid delivery to the circulatory system and bypass the liver’s filtration mechanism, which digested medicines would normally be subject to. DehydraTECH’s lymph vessel delivery approach also has several advantages over digested medicines by decreasing concerns about taste, improving neurological delivery across the blood brain barrier, reducing the amount of drugs needed for usefulness, and decreasing the risk of side effects. The technology is also relatively low-cost, with the capacity to produce up to 400,000 consumer packaged goods though existing manufacturer relationships. “Lexaria’s technology is enabling increased market share and sales growth for our continually growing list of corporate clients,” CEO Chris Bunka said of the company’s brand partnerships earlier this summer (https://ibn.fm/PfLMa). “We are delighted to help these innovators of today and leaders of tomorrow offer their clients superior performance and experiences that competitors simply cannot match, and we are highly anticipatory of additional growth to come.” For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Lobeline is Los Angeles-based with reach that extends from California to New York, Chicago, and Canada
• Fan Pass has released version 2.0, and continues the implementation of the Company’s growth strategy
• Artist Pro Services fuel this growth strategy with the inclusion of custom logo, merchandise and promotional designs

To help facilitate its Fan Pass live streaming artist platform’s growth strategy and brand-building efforts, mobile technology and marketing company Friendable (OTC: FDBL) announced that it was contracting a new public relations and digital partner, Lobeline Communications. The addition of Lobeline will help provide more exposure to what Fan Pass has to offer artists and fans alike (https://ibn.fm/bUJkO). Lobeline was founded by Phil Lobel, a former concert promoter, and serves the entertainment industry and music-related clients with PR, social media, and influencer marketing campaigns. Lobeline’s primary location is in Los Angeles, California, with additional offices reaching San Francisco, New York, Chicago, and Toronto, which can help extend the reach of Fan Pass across the country and international borders. The Fan Pass platform was founded by Robert A. Rositano Jr. (“CEO”) and his brother Dean Rositano (“CTO”) in July 2020. Together, they wanted to provide a virtual stage for musicians and their fans to come together. Since the original launch, Fan Pass has released version 2.0 of their new mobile and desktop applications, upgraded the experience for both artists and fans, and is continuing to move forward with their artist and fan acquisition outreach and monthly promotional contests that pay the artist to perform. According to Robert A. Rositano, the addition of Lobeline is a step in the right direction for Fan Pass, and the execution of the plan previously commenced. “We feel Fan Pass has secured the absolute correct partner for the Company’s growing needs in this entertainment sector and will continue adding to what is already a very talented and diverse team as we look to take advantage of several existing and new opportunities that we are currently engaged in. Our team is excited about these next stages of growth and expansion,” he explained. Fan Pass offers artists multiple avenues to earn revenue, including a piece of the monthly subscription fee that fans pay to access their favorite artist’s content, merchandise, and exclusive events. Artists have the tools they need to create, stream, and promote their art using the streaming gear and other services available in a one-of-a-kind Artist Pro Services shop. Fan Pass Artist Pro services offer artists unique tools to promote their music and brand. These services include artist/band logo, merchandise, and marketing designs. Each comes with three tiers to choose from and ranges in pricing from just under $50 to $400 depending on the level of services needed. The process is easy – artists fill out the form in the Pro-Services section, designers create mock-ups for the artist to review, and once the changes have been finalized, the artist approves the final graphics. In the future, Fan Pass also plans to add non-fungible tokens (“NFTs”), increasing the revenue opportunities of the artists currently on the platform. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• InnerScope Hearing Technologies is a direct-to-consumer manufacturer, distributor, and retailer of hearing aids and assorted hearing-related products
• The White House has recently published initiatives designed to de-regulate the hearing aid market, including allowing hearing aids to be purchased over the counter as well as negating the need for the devices to be prescribed by a medical professional
• InnerScope has introduced a series of free, self-administered hearing screening kiosks which can help consumers identify hearing loss and the severity of their hearing loss as well as the type of loss, and subsequently, recommend the best hearing aid for their particular case
• InnerScope has recently launched its product range on FSAstore.com, HSAstore.com, and WellDeservedHealth.com, as well as its own e-commerce site, MyHearIQ.com.

Although approximately 28.8 million Americans could benefit from wearing hearing aids today, fewer than 16 percent have ever used them. In fact, studies have shown that most people wait nearly 15 years from the time they know they have hearing loss until they actually purchase their first hearing aids – often citing elevated device prices as a barrier to purchase (https://ibn.fm/xFSCM), even though untreated hearing loss could be a precursor to more significant mental health problems, including depression, social isolation, and serving as an early indicator of Alzheimer’s disease. InnerScope Hearing Technologies (OTC: INND), a manufacturer and distributor/retailer of DTC, FDA registered, Bluetooth app-controlled hearing aids and personal sound amplifier products (“PSAPs”), as well as various hearing-related treatments, has sought to target this issue, thereby improving the quality of life of the 70 million people in North America and the 1.5 billion people worldwide suffering from hearing-related issues. On July 9, 2021, the White House published a new directive on promoting competition within the American economy through the planned promulgation of initiatives such as allowing hearing aids to be sold over the counter at drug stores and reducing the cost of hearing aids from the current average of $5,000 per pair (https://ibn.fm/bqJM0). InnerScope has positioned itself to benefit from the potential shift in regulations through its innovative in-store free self-check hearing screening kiosks (“Hearing Kiosks”) and a customer monthly subscription model, which can help consumers purchase superior quality hearing aids at an affordable monthly price. InnerScope has started its national rollout of Hearing Kiosks at a string of national pharmacy chains, big-box retailers, and grocery chains across the country. The Hearing Kiosks are equipped with the world’s first ‘hearing triage’ artificial intelligence pattern recognition software, which has a unique ability to classify both the degree of hearing loss and the type of loss. Following detection, the Hearing Kiosks can then make recommendations for one of InnerScope’s hearing devices and advise whether the consumer should seek further attention from a medical professional should follow-up testing be necessary. In addition to providing free, self-administering hearing screening kiosks, InnerScope has also made hearing aids more accessible to the public by recently launching their product range on FSAstore.com, HSAstore.com, and WellDeservedHealth.com for the 70 million consumers currently enrolled in flexible spending accounts, health savings accounts, and employers’ health incentive programs. Moreover, the company has recently launched its dedicated online store, www.MyHearIQ.com enabling any customer with a smartphone to personalize each hearing device to their specific needs using an onboard in-ear custom-fit self-testing feature through the free HearIQ app ‎ offered at the apple app store hearIQ on the App Store (apple.com) and Google Play Store hearIQ – Apps on Google Play. InnerScope is operating at the vanguard of the hearing aid market, working towards shifting hearing health care away from traditional brick-and-mortar clinics and towards customers’ homes by providing a unique and affordable solution to resolve consumers’ hearing needs. With the global hearing aid market expected to reach $11.02 billion by 2028, representing an earnings growth CAGR of 7.4% over the 2021-2028 interim, InnerScope Hearing Technologies is poised to benefit from a rapidly expanding total addressable market while simultaneously gaining from the United States Government’s recent initiatives to promote competition and broaden customer choice within the sector. For more information, visit the company’s website at www.INND.com and the company’s e-commerce website: www.MyHearIQ.com. NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

• American Cannabis Partners has focused on the safety of shareholders’ investments from day one
• CEO brought the culture and story of the Jamaican people to influence the US cannabis industry
• ACP seeks to improve the lives of individuals through cannabis and business in all that it does

When it comes to building steady growth and reducing risk, Stephen Jordan, CEO of American Cannabis Partners (“ACP”) focuses on “assets, assets, assets — and then build the operations out.” This is a rarity within the cannabis industry where most companies create a product first and if something happens where they are unable to make that product, they go under. ACP does business differently. The goal is to stay afloat, regardless of what happens regarding regulation changes in the cannabis industry. As a multi-state operator, it can pivot within the fluctuations of each state’s laws. The ability to liquidate, move and still survive was and is a founding strategy that allows it to protect its shareholders. The company’s ethics demonstrate “people before profit” at every step. From a strategic startup to maintained relationships with growers in Jamaica and shareholders, ACP believes and practices social and emotional intelligence. As a fairly new industry, cannabis runs risks for both the companies and the shareholders who invest in them. ACP worked from day one to eliminate those risks for its shareholders by first raising capital and then investing that money into assets in cannabis-friendly states where there is population demand, agricultural zoning, and available licenses. The company does not go into debt to obtain these assets but is committed to remaining debt-free and cash-flow positive. Cost-effective measures are immediately put into place once the sale is complete in order to increase the market value of any real estate it has acquired. This is what gives the shareholder extra safety if the laws do suddenly change or if the industry bottoms out. As a cash-flow positive company, ACP will be able to liquidate, pivot and take care of its shareholders first. The shareholders aren’t the only people ACP is committed to. The people and culture of Jamaica won Jordan’s heart during a three-year tenure as the Director of Operations for a U.S. based company operating in the Jamaican cannabis space. The relationships and family he built in Jamaica impacted him greatly. When Jordan left, he knew that the U.S. cannabis space would benefit greatly from the Jamaican experience, so he brought it with him. “One of the greatest things about being in Jamaica is the happiness of the people,” said Jordan during a recent podcast appearance on Bell2Bell. “Even in the face of adversity, poverty, political turmoil, and everything else, they’re still happy people — constantly happy people. Cannabis is a big attribute to that.” It was the culture and the story that Jordan wanted to bring back with him, and he did with key employees such as Lead Grower Junior Gordon. Gordon is recognized as one of the top-ranked growers in the world. With a talented team, he monitors daily plant health to ensure optimal growth of high-quality, uniform plants. But it’s not just the people that Jordan brought back with him to grow ACP. The people of Jamaica and the growers have not been forgotten. ACP is a high-paying grower that works hard to maintain a positive and serious relationship with the people of Jamaica. It seeks to improve the lives of individuals through cannabis and business in all that it does. Three complementary business segments hold this multi-state cannabis company’s focus — real estate, acquisition and development of proprietary assets, and ongoing cultivation operations. An important goal for 2021 is to bring the website fully online to capitalize on the company’s revenue and on building solid relationships with its consumers. For more information, visit the company’s website at www.ACPFarms.com. NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://ibn.fm/ACP

• BevCanna is rapidly increasing its footprint within the Canadian functional beverages market
• The company has recently entered into a sales service agreement with Velvet Management Inc., Canada’s leading cannabis sales agency
• BevCanna has also separately announced that its highly sought-after products will now be distributed by the British Columbia Liquor Distribution Branch, Canada’s fourth largest provincial cannabis product retailer
• The moves bode positively for BevCanna in consolidating its position as a preeminent white label partner operating within the Canadian cannabis market

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), a diversified health & wellness beverage and natural products company developing and manufacturing a range of alkaline, plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients has recently announced a series of new corporate developments, designed to further broaden its commercial prospects moving forward. BevCanna announced that it had recently entered into a sales service agreement with Velvet Management Inc., Canada’s leading cannabis sales agency. Shortly thereafter, the company simultaneously revealed that it had signed a number of product purchase agreements with the British Columbia Liquor Distribution Branch (“BCLDB”), a testament to BevCanna’s rapidly expanding distribution network across Canada. This agreement comes on the heels of two similar agreements with Alberta Gaming and Liquor Commission (“AGLC”) and Ontario Cannabis Store (“OCS”). Functional drinks and drinks based on plant derivatives — including those containing cannabis- or hemp-derived ingredients like cannabidiol (“CBD”) or tetrahydrocannabinol (“THC”) — have rapidly established themselves as one of the fastest-growing verticals within the North American beverage industry, with a recent study forecasting the global cannabis drinks sector to triple in value to $5.8 billion by 2024. While a number of large global brands, including AB InBev and Molson Coors have recently announced plans to produce CBD-containing products, there is no doubt that the cannabis drinks market remains largely untapped (https://ibn.fm/2NHkf). A recent report by industry think-tank (https://ibn.fm/wtV1O), Expert Market Research, elaborated on the potential within the North American cannabis beverage market: “Cannabis consumers are shifting their interest from smoking cannabis to other ways, like beverages, tinctures, chocolates, and other edibles,” the report noted. “Consumers are willing to consume concentrated and cannabis-infused products, which successively is anticipated to support the market growth. Cannabis beverages are predicted to exchange other marijuana-infused consumables, like chocolates, cookies, brownies, and confectionaries like gummies and candies, which are considered to be not healthy. This factor is predicted to spice up the demand for cannabis drinks over the forecasted period.” BevCanna has sought to leverage the ongoing growth within the sector through its full-service white label beverage manufacturing solution, enabling the company’s partners to efficiently and economically gain access to the burgeoning Canadian functional beverage market. BevCanna possesses a 40,000 square-foot beverage manufacturing facility which is HACCP-certified, with capabilities including blow-molding, dosing, carbonation options, filling and capping, pressure-sensitive and shrink-sleeve label applications, flash pasteurization, QA testing, and packing/palletizing for shipment. Moreover, through its distribution network featuring over 3,000 points of retail distribution across Canada, BevCanna enables its partner brands to rapidly expand their geographical footprint within the Canadian market. BevCanna recently partnered with Velvet Management, a premier full-service cannabis marketing agency that represents Canadian Licensed Producers, at all levels of selling and marketing, to government buyers and private retailers (https://ibn.fm/au6Hu). “Engaging Velvet, a leading agency in the Canadian market, will accelerate our sales penetration nationally and build awareness through its substantial network of retailers,” said Melise Panetta, President of BevCanna. The company shortly followed up on the Velvet Management tie-up news with the announcement of a collaboration with the British Columbia Liquor Distribution Branch, Canada’s fourth largest provincial distributor in terms of cannabis sales, boasting over $1 billion on an annual basis (https://ibn.fm/n1ygM). The BCLDB has recently revealed that it will carry Keef Brands’ popular Bubba Kush Root Beer and Orange Kush Classic Soda products within their retail network, a move that will be decidedly beneficial for BevCanna, with the company acting as the exclusive manufacturer of Keef Brands products in Canada. (As already mentioned above, this comes on the heels of two similar agreements with AGLC and OCS). For more information, visit the company’s website at www.BevCanna.com. NOTE TO INVESTORS: The latest news and updates relating to BVNNF are available in the company’s newsroom at http://ibn.fm/BVNNF

• Through HealthTab, its flagship offering, Avricore is enabling consumers to access important health information in a convenient way and at a time that is fitting for them
• HealthTab is a turnkey point-of-care testing solution that combines a secure, cloud-based platform with point-of-care technologies
• In a rapidly evolving world of healthcare that has seen consumers become more health-conscious and prompted the adoption of digital technologies, Avricore is playing a critical role
• Avricore has appointed Oak Hill Financial Services Inc. to provide the company with investor relations and advisory services.

When reflecting upon the impact of the COVID-19 pandemic, it is hard to miss the fact that it has accelerated change across the global health care ecosystem. It has made consumers more health-conscious, with many taking more initiative, as evidenced by their willingness to utilize technologies to get information on health issues, as well as track their health and use the data generated to make health-related decisions. They are also accessing and utilizing their medical record data. These new consumer preferences have meant that health delivery organizations (“HDOs”) have had to adapt and innovate within a short time to remain relevant. As a result, HDOs are transforming their care models by including safe, secure, and virtual care delivery, leveraging partnerships, reimagining the workforce, and more. Additionally, the pandemic has exposed the ever-expanding gap between the demand for health care and the supply of resources, including staff, further solidifying the awareness that widespread adoption of digital technologies, such as artificial intelligence (“AI”), cloud computing, and virtual care delivery, is needed to bridge this gap (https://ibn.fm/RwMwL). In this rapidly evolving world of health care, Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF), a health diagnostics technology innovator, is taking part in the digital transformation as well as satisfying emerging consumer preferences through its flagship offering, HealthTab(TM). A turnkey point-of-care testing solution that combines a secure, cloud-based platform with best-in-class point-of-care technologies to help improve the quality of life for patients living with chronic illnesses, HealthTab enables consumers to access important health information conveniently and at a time that is fitting for them. This is especially critical at a time when increasingly health-conscious consumers are looking for these exact technologies and services. “What HealthTab does is it creates a space where a patient can take direct agency over their health,” stated Avricore CEO Hector Bremner (https://ibn.fm/0Bro6). “They can walk into their pharmacy, they can ask that question, and they can get information that they can act on now.” Avricore’s pharmacy-based approach to providing convenient and timely care appears to bode well with the ongoing transformation of the health care system, which has expanded the role of pharmacists. Their responsibilities are evolving to include providing direct care to patients in tandem with physicians through collaborative practice agreements (“CPAs”). Some of these expanded responsibilities include performing patient assessment activities, ordering and interpreting lab tests, creating therapeutic plans, and using initiating, adjusting, or discontinuing drug treatment (https://ibn.fm/8YA9J). In understanding this growing importance of pharmacies and pharmacists, Avricore is using its HealthTab platform to turn the former into community diagnostic centers, enabling pharmacists to seamlessly and successfully take up their expanded responsibilities, thus playing a greater role in primary health services. Avricore has since partnered with Shoppers Drug Mart, which boasts an extensive network across Canada comprising more than 1,300 stores. Following a successful pilot, HealthTab is expected to roll out across more stores, further expanding Avricore’s Canadian coverage. Meanwhile, Avricore announced on September 13 that it had appointed Oak Hill Financial Services Inc., a Toronto-based leading Canadian marketing and distribution firm, to provide investor relations and advisory services. “More specifically, Oak Hill will provide services such as drafting marketing materials and reaching out to its Canadian investor network to expand Avricore’s visibility in the financial community,” explains the announcement (https://ibn.fm/NxucC). For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• The approval by the Marijuana Regulation Agency represents RWB’s authorization to move forward with the operational strategy of its subsidiary RWB Michigan, LLC
• Michigan provides access to a market with approximately 10 million people and a consumer pool responsible for $171 million in sales – resulting in the generation of more than $23 million in tax revenue for the state’s roads, schools, counties, and municipalities
• The Sanderson property in Florida has been built to GMP specifications and is a 4,800 square foot standalone facility that is expected to help bridge the gap and satisfy the fast-growing demand in the cannabis edibles market

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF), formed when privately held MichiCann Medical Inc. merged with publicly traded Tidal Royalty in 2019, is an innovator of American cannabis – adhering to the highest ethical, manufacturing, education, branding, and employment standards in the industry. The company is a superstate operator, leveraging a sizable footprint to dominate the areas in which it operates. RWB recently announced that it received adult-use (recreational use) prequalification status according to the licensing provisions of the Michigan Regulation and Taxation of Marihuana Act (“MRTMA”) and the associated rules through a wholly owned subsidiary, RWB Michigan, LLC. The approval by the Marijuana Regulatory Agency (“MRA”) represents the authorization of RWB to move forward with the full operational strategy in Michigan and the complete licensing process for the intended facilities (https://ibn.fm/iZYdM). “Michigan provides RWB access to a market with a population of approximately 10 million people, and where, in the month of July, cannabis consumers were responsible for $171 million in sales generating more than $23 million in tax revenue for Michigan’s roads, schools, municipalities, and counties,” CEO and Chairman of RWB, Brad Rogers, said. Michigan is not the only state where RWB is excelling – the company’s Sanderson property in Florida has been built to GMP specifications to capitalize on the growing cannabis derivatives market. The expectation is that the Florida medical cannabis market will reach $1.5 billion in sales during 2021, which marks a growth of 53% over 2020. Medical and recreational use cannabis is expected to be legal in Florida by 2023, with the overall market expected to reach $2.6 billion by 2026 (https://ibn.fm/25uDQ). The Florida facility is a 4,800 square foot standalone structure and is expected to help satisfy the fast-growing demand in the cannabis edibles market. “We are very pleased to have completed this state-of-the-art production facility ahead of time and begin production this month. We will begin with premium specialized confectionary offerings as finished retail-ready packages where medical patients will be able to select from a variety of different products,” RWB’s GM Jim Frazier said. “We are confident this new facility, coupled with our expert staff of edible specialists, can produce a market-leading offering” (https://ibn.fm/RxbUE). RWB enters into strategic brand acquisitions and partnerships that aim to help the company expand its presence and position, with the goal of being a key player in the United States cannabis market. The company is always diligently searching for brands to acquire and bring additional value to expand its footprint. Currently, the company’s brand portfolio consists of Platinum Premium Cannabis Products (“PV”), High Times(R), and Mid-American Growers. Upon completion of RWB’s current proposed investments and acquisitions, the company will be one of the largest companies in the cannabis market. Currently, assets (closed or in closing-stage) are located within Michigan, Illinois, Florida, Oklahoma, Massachusetts, and California. For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

• Although an often unspoken of medical disorder, Hypoactive Sexual Desire Disorder affects approximately 9.5 million women in the U.S. alone
• The project gathers some of the world’s leading researchers in female sexual desire and psychedelics
• This is the first-of-its-kind psychedelic-based treatment program targeting this disorder, with potential global implications
• Clinical trials of MDMA as a treatment for PTSD have shown some success due to targeting the pathways that process fear
• MINDCURE is working with a molecule that will be first-to-market – MDMA is predicted to be approved by 2023 – this brings them closer to the money

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a diversified life sciences company currently at the forefront of innovating and improving mental health through the research and use of psychedelic compounds, is pleased to announce the launch of its “Desire Project” to address and treat female Hypoactive Sexual Desire Disorder (“HSDD”) with MDMA-assisted psychotherapy. The Desire Project is the first-of-its-kind study targeting this sexual disorder which affects an estimated 9.5 million premenopausal women in the United States alone. The benefits of the study could potentially impact women and relationships on a worldwide level (https://ibn.fm/uC78c). HSDD is a common sexual disorder characterized by a persistent, low sexual drive with emotional distress that is not associated with an existing medical or relationship problem. According to current estimates, 40% of women in the US have self-reported low sexual desire, with HSDD affecting 10% of adult women and 14% of premenopausal adult women. Men can also suffer from HSDD. “MINDCURE has identified a gap in the market, and I think that with the team we have built to execute this project, we can help those seeking improved desire in a new way. We know that sexual health contributes to overall wellbeing and that studies relating to HSDD suggest that female desire has deep roots in the mind,” MINDCURE President and CEO Kelsey Ramsden said. “Women’s desire issues have not been adequately addressed to date, and we believe that treatment incorporating MDMA and psychotherapy has real promise as it may target those roots of desire in the mind and unlock healing for women lacking desire.” In clinical trials using MDMA, some success has been shown in post-traumatic stress disorder (“PTSD”) patients. The MDMA treatment works on the brain’s pathways related to fear. It can help enhance fear memory extinction, modulate fear memory reconsolidation, and even bolster the social behavior in animal tests. MINDCURE has spent six months planning the upcoming Desire Project with a strong emphasis on how MDMA may ease some of the fear factors in women, which could play a large role in female-related sexual disorders that are not currently treatable by methods or medications on the market. The Desire Project comprises some of the world’s leading researchers in female sexual desire and psychedelics. These world-renowned names include:

• Dr. Anita Clayton (Professor and chair of the Department of Psychiatry and Neurobehavior Sciences and a Professor of Clinical Obstetrics and Gynecology at the University of Virginia), Dr. Jennifer Mitchell (lead author of MAPS MDMA-assisted therapy for PTSD study),
• Dr. Cindy Meston (directs the Female Sexual Psychophysiology Laboratory at the University of Texas in Austin),
• Dr. Robert Pyke (leader of the Addyl project, a drug used to treat the symptoms of HSDD and has author of over 100 peer-reviewed publications in the last 18 years), and
• Dr. Sherry Walling (a practicing, licensed clinical psychologist with a master’s degree in theology and emphasis on trauma).

“During my decades as a psychiatrist, I’ve seen first-hand the limitations of existing treatments. This is an exciting opportunity to find a potentially more effective and better tolerated treatment for women affected by this disorder,” Mind Cure Health CMO Dr. Joel Raskin, MD, said (https://ibn.fm/4MJOp). Living with HSDD can damage the lives of the women it affects, causing depression and anxiety – potentially destroying personal relationships. Through the Desire Project, MINDCURE hopes to tackle the challenges faced by women suffering from this disorder. For more information, visit the company’s website at www.MindCure.com. NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

• What: USA CBD Expo 2021
• When: October 28-30, 2021
• Where: Chicago, Illinois
• Details on the Venue: Hosted at the famous McCormick Place convention center in downtown Chicago
• Key Stats: 50+ field experts, 300 unique vendors, and thousands of high-quality products from all over the globe

The skyrocketing global CBD and hemp markets have only continued to dominate the industry after the COVID-19 pandemic. Now, professionals from around the world can finally come together to discuss the knowledge, experience and advice they’ve acquired this past year at the USA CBD Expo 2021 in Chicago, Illinois. The event is hosted from October 28-30 at the famous McCormick Place convention center and is considered the largest CBD expo series in the nation. The massive 2 billion dollar venue space and recent advances for cannabis legalization in Chicago makes it the perfect setting for this global CBD showcase (https://ibn.fm/1AoKh). The windy city also hosts massive market potential for the CBD and hemp industry due to foot traffic alone, as more than 58 million travelers visit the windy city each year. Additionally, since its legalization, retail cannabis sales within the state have skyrocketed to an estimated $40 million in revenue. In addition to the city’s impressive statistics, the convention center is conveniently located near several luxury lodgings already blocked out for the event, like the Hilton Garden Inn and Home2 Suites. The convention’s presentation sponsor, 3Chi, stays at the forefront of this booming industry by creating a professional gathering for experts and business owners from various fields of CBD and hemp. The American-made company prides itself on its biochemist formulated and lab-tested hemp products. Their impressive list of participants includes more than 50 experts in the CBD and hemp field and hundreds of unique vendors displaying thousands of high-quality products. The scheduled talks range from marketing and finance to niche topics like sports medicine, sustainability, farming, and even animal medicine. Some of the highly anticipated talks include actor Jason Gann from Wilfred Hemp & CBD and Wilfred Cannabis, Scott Frohman and The Power of Medicinal Mushroom Extracts, as well as discussions surrounding delta-8, psychedelic education, and CBD for sexual wellness. Four possible ticket types are available for the convention, ranging from Industry Buyer and Industry Professional passes to General Admission and Press passes. Each ticket type has applicable perks and most choices encompass the entire three-day event to professional networking opportunities. Additionally, vendors may receive a discount if they sign up for multiple days of the event. Tickets for the Chicago showcase are available for purchase on the event’s website (https://ibn.fm/FeBYp). For further information about USA CBD Expo 2021 or to learn how to buy tickets, visit the event’s website at https://usacbdexpo.com